PUBLIC MEETING ON DEVICE GENERAL/SPECIFIC INTENDED USES GUIDANCE UNDER CONSIDERATION BY FDA; HIMA FORMING TASK FORCE TO PROVIDE INPUT ON POLICY
This article was originally published in The Gray Sheet
FDA may seek input on the types of specific intended uses covered by a general device claim through a public meeting, Joseph Sheehan, regulations staff director in FDA's Center for Devices and Radiological Health, said Feb. 4 at a Health Industry Manufacturers Association meeting in Washington, D.C. CDRH plans to publish a guidance on the subject before the Aug. 18 deadline stipulated in the FDA Modernization Act.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.